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Renal dysfunction is a severe complication of advanced
HIV disease. We evaluated the impact of highly active
antiretroviral therapy (HAART) on renal function among
HIV-infected Ugandans in the Home-Based AIDS Care clinical
trial. The patients presented with symptomatic HIV disease or
CD4 cell count p250 cells/mm3 and creatinine clearances
above 25 ml/min determined by the Cockcroft-Gault
equation. Of the 508 patients at baseline, 8% had a serum
creatinine over 133 lmol/l and about 20% had reduced
renal function evidenced by a creatinine clearance between
25 and 50 ml/min. After 2 years of HAART, the median serum
creatinine was significantly decreased by 16% while the
median creatinine clearance significantly increased 21%.
The median creatinine clearance of patients with renal
dysfunction at baseline, increased by 53% during 2 years
of treatment. In multivariable analysis, a baseline creatinine
above 133 lmol/l, a weight gain of more than 5 kg over the
2 years, female gender and a WHO stage 4 classification
were all associated with greater improvements in creatinine
clearance on HAART. Our study shows that renal dysfunction
was common with advanced HIV disease in Uganda but
this improved following 2 years of HAART.
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Renal dysfunction progressing to end-stage renal disease is
a common complication of advanced human immuno-
deficiency virus (HIV) infection, particularly among African
Americans.1–4 Although HIV-associated renal disease has been
documented in sub-Saharan Africa,5–9 little is known about its
prevalence or impact. Highly active antiretroviral therapy
(HAART) may be protective against10 and therapeutic for11
HIV-associated renal disease. However, renal dysfunction may
complicate antiretroviral treatment because some medications
require dose adjustments. Certain antiretrovirals, such as
tenofovir12,13 and indinavir,14 can also cause renal dysfunction.
To better understand changes in renal function associated with
HAART in resource-limited settings where laboratory-based
monitoring may not be routinely available, we evaluated data
from persons participating in the Home-Based AIDS Care
(HBAC) project in rural Uganda.
RESULTS
We evaluated 508 participants who had been followed for at
least 24 months after HAART initiation and had creatinine
results at baseline and at their 12-month and 24-month
follow-up visits. Participants were initiated on stavudine plus
lamivudine with either nevirapine (496 participants, 98%) or
efavirenz (12 participants, 2%). The study population
(n¼ 508) included 301 (59%) women and had a median
age of 39 years, CD4 cell count of 122 cells per mm3, HIV
viral load of 244 500 copies per ml, weight of 54 kg, and body
mass index (BMI) of 19.6 kg/m2 at baseline.
The baseline median creatinine was 97 mmol/l (1.10 mg
per 100 ml), and 43 (8%) of 508 participants had a creatinine
of X133 mmol/l (1.50 mg per 100 ml). The baseline median
creatinine clearance (CLcr) by the Cockcroft–Gault equation
was 63 ml/min, and 101 (20%) of 505 participants had renal
dysfunction (CLcr 25–50 ml/min). Baseline CLcr could not be
calculated for three participants because their baseline weight
was not recorded. Characteristics associated with renal
dysfunction at baseline in multivariate analysis included
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female gender, age X35 years, World Health Organization
(WHO) stage 4 disease, baseline weight p60 kg, and a base-
line BMI o18 kg/m2 (Po0.05). Renal dysfunction at base-
line, however, was not associated with the baseline viral load
(P¼ 0.12) or CD4 cell count (P¼ 0.74).
Among the 508 participants who survived and received 24
months of HAART, median creatinine decreased by 16 mmol/l
(16% decline, Po0.0001) and median CLcr increased by
13 ml/min (21% increase, Po0.0001) (Table 1). The
proportion of participants with renal dysfunction decreased
from 20% at baseline to 6% by month 24 (Po0.0001).
Similar improvements in renal function were observed when
the simplified modification of diet in renal disease (MDRD)
equation was used to estimate glomerular filtration rate
(Table 1). Participants with renal dysfunction at baseline
(n¼ 101) had the most dramatic improvements in CLcr.
Their median CLcr increased by 23 ml/min (53% increase,
Po0.0001 compared with the improvement in CLcr among
participants with a baseline CLcr of 450 ml/min) over 24
months on HAART (Figure 1). Among HBAC participants
with diarrheal disease (a surrogate for dehydration) at
baseline (n¼ 35), there was no difference in CLcr improve-
ments on HAART compared with participants without
diarrhea. Among participants who achieved viral load
suppression (viral load of o400 copies per ml) after 1 year
on HAART (n¼ 485, 96%), there was a trend toward a
greater improvement in CLcr (P¼ 0.13). In multivariable
analysis, baseline creatinine of X133 mmol/l (1.5 mg per
100 ml), a weight gain of X5 kg on HAART, female gender,
and WHO stage 4 disease were all associated with a greater
improvement in CLcr (Table 2). Although renal function
improved in the majority of participants, some participants
had a decline in CLcr over 24 months on HAART. Among the
404 HBAC participants with a CLcr 450 ml/min at baseline,
the CLcr of 19 (5%) participants declined to p50 ml/min
after 24 months on HAART. These participants experienced
a median CLcr decline of 13 ml/min, although 18 of 19 had
achieved viral load suppression (o400 copies per ml) on
HAART. At 24 months, no participant had a CLcr of less than
25 ml/min and the lowest CLcr was 37 ml/min.
As a separate analysis, we compared the baseline renal
function of the 72 HBAC participants who died within the
first 12 months of starting HAART with the 508 renal analysis
participants who received HAART and survived 24 months.
No deaths in HBAC were known to be due to renal failure,
although a definite cause of death could not always be
determined. HBAC participants who died within the first 12
months of starting HAART had a baseline median CLcr of
63 ml/min (P¼ 0.35 compared with renal analysis partici-
pants who also had a baseline median CLcr of 63 ml/min)
and 19 (29%) deceased participants had baseline renal
dysfunction (P¼ 0.09 compared with renal analysis partici-
pants of whom 20% had baseline renal dysfunction).
DISCUSSION
Renal dysfunction was common in this population of rural
Ugandans with advanced HIV disease, but generally im-
proved during 2 years on HAART. The greatest improve-
ments occurred in patients with renal dysfunction at baseline.
Our results suggest that the inability to monitor renal
function should not be a contraindication to providing
Table 1 | Renal function during 24 months on HAART (n=508)
Month 0 Month 12 Month 24
Median creatinine mmol/l 97 88 81w
Interquartile range (IQR) mmol/l (80–107) (75–103) (72–95)
Creatinine X133 mmol/l
(1.5 mg per 100 ml), n (%)
43 (8%) 17 (3%) 13 (3%)z
Median CLcr (ml/min)a 63 73 76y
IQR (ml/min) (53–77) (61–87) (65–91)
CLcr p50 ml/mina, n (%) 101 (20%) 38 (8%) 32 (6%)||
CLcr p60 ml/mina, n (%) 212 (42%) 116 (23%) 91 (18%)z
Median MDRD (ml/min per 1.73 m2) 83 90 96**
IQR (ml/min per 1.73 m2) (69–98) (76–108) (82–114)
MDRD p60 ml/min per 1.73 m2, n (%) 59 (12%) 30 (6%) 18 (4%)ww
Median weight (kg)a 54 57 57z
IQR (kg) (48–60) (52–63) (52–63)
CLcr, creatinine clearance; HAART, highly active antiretroviral therapy; IQR,
interquartile range; MDRD, modification of diet in renal disease.
wPo0.0001 compared with months 0 and 12, Wilcoxon signed-rank test.
zP=0.0002 compared with month 0 and P=0.4 compared with month 12, McNemar’s
test.
yPo0.0001 compared with month 0 and P=0.002 compared with month 12,
Wilcoxon signed-rank test.
||Po0.0001 compared with month 0 and P=0.5 compared with month 12,
McNemar’s test.
zPo0.0001 compared with month 0 and P=0.02 compared with month 12,
McNemar’s test.
**Po0.0001 compared with months 0 and 12, Wilcoxon signed-rank test. The
correlation coefficient for CLcr versus MDRD was 0.68 at month 0, 0.73 at month 12,
and 0.61 at month 24.
wwPo0.0001 compared with month 0 and P=0.045 compared with month 12,
McNemar’s test.
aThree participants did not have baseline weights.
250
200
150
100
50
CL
cr
 (m
l/m
in)
CLcr 50 ml/min
At baseline (n=101*)
CLcr 50 ml/min
At baseline (n =404*)
0
Median
Baseline
44
Baseline
67
12 months
66
12 months
75
24 months
67†
24 months
79‡
Figure 1 | Box-whisker plot of CLcr over 24 months on HAART
stratified by baseline renal function. Top and bottom boxes
indicate 75th and 25th percentiles, respectively. Bars indicate
minimum and maximum. Filled squares indicate median (ml/min).
The median values are also indicated along the x axis. wPo0.001
compared with month 0 and P¼ 0.24 compared with month 12,
Wilcoxon signed-rank test. zPo0.001 compared with month 0 and
P¼ 0.002 compared with month 12, Wilcoxon signed-rant test.
*Three participants did not have baseline weights.
926 Kidney International (2008) 74, 925–929
o r i g i n a l a r t i c l e PJ Peters et al.: Renal function improves on HAART
first-line HAART and support current WHO guidelines,
which do not recommend monitoring renal function with
first-line HAART in resource-limited settings.
The pre-HAART prevalence of renal dysfunction in this
setting was greater than rates observed in several US cohort
studies15,16 and a cross-sectional study from Kenya.7 Two
factors likely explain this discrepancy. Renal disease, such as
HIV-associated nephropathy (HIVAN), typically worsens
with advanced HIV disease,17 and the participants in this
clinical trial uniformly had advanced HIV disease at baseline.
Additionally, in the US conditions such as HIVAN occur
primarily in individuals of African descent,18 suggesting that
Africans may also be at greater risk for this complication.
In resource-limited settings, the ability to monitor renal
function is often limited. If, as our data suggest, renal
function will improve in most patients with advanced HIV
disease who initiate HAART, a rational approach would be to
use standard weight-based dosing without adjustment for
renal function at the initiation of antiretroviral therapy, even
for patients in whom renal dysfunction can be identified.
Such a strategy avoids sub-optimal HAART dosing, which
could result in virologic treatment failure. Where monitoring
is available, patients with renal dysfunction at HAART
initiation may warrant repeat renal function testing during
the first few months of treatment. If renal function does not
improve despite HAART, then antiretroviral dose adjust-
ments based on renal function should be considered. As
participants did not receive tenofovir or indinavir as part of
their initial HAART regimens, this suggested strategy cannot
be extrapolated to tenofovir- or indinavir-based regimens
without further evaluation. Although renal function im-
proved in the majority of participants in this study, 5% of
participants had a significant decline in renal function despite
achieving viral load suppression on HAART. This decline in
renal function for a minority of participants may reflect HIV-
associated renal disease that does not improve with HAART
or other renal pathologies that would not be expected to
respond to HAART.19
There were several limitations in this study. First, the
underlying etiology of renal disease was unknown in study
participants, and urine specimens were not available to
evaluate for proteinuria. Rates of diabetes and hypertension,
although believed to be low in rural Uganda, were also not
defined in this study. Second, we do not have adequate data
to assess how HAART improved renal function. Some
improvement in renal function may have occurred from an
overall improvement in general health. For instance, chronic
HIV-associated diarrhea in persons with advanced disease
can cause chronic dehydration, which could rapidly improve
with HAART. Notably, however, in our study reported
diarrhea (our best surrogate for dehydration with advanced
HIV disease) did not correlate with improvements in renal
function on HAART. HAART may also have had a more
direct effect on renal function. Several studies have suggested
that HAART can slow or reverse the progression of HIVAN
and other HIV-related renal diseases,10,20–23 especially in the
context of advanced HIV infection and impaired baseline
renal function.9 In our study, renal function continued to
improve from month 12 to month 24 on HAART, suggesting
the gradual improvement of a chronic renal condition. Third,
the accuracy of the Cockcroft–Gault equation to estimate
renal function is unknown in the context of advanced HIV
disease in Africa, especially with AIDS-associated wasting and
cachexia.24,25 In addition, lower rates of renal dysfunction
Table 2 | Multivariablea analysis of factors associated with improved CLcr over 24 months on HAART (N=501b)
n (%) Adjusted mean change CLcr, ml/min (95% CI) Adjusted P-value
Creatinine at baseline
X133mmol/l (1.5 mg per 100 ml) 43 (9%) 30 (24–36) o0.0001
o 133mmol/l (1.5 mg per 100 ml) 458 (91%) 11 (9–13)
Weight gain on HAART
X5 kg 149 (30%) 20 (17–24) o0.0001
o5 kg 352 (70%) 9 (7–12)
Gender
Female 296 (59%) 16 (13–18) o0.0001
Male 205 (41%) 8 (5–11)
WHO stage at baseline
Stage 4 41 (8%) 20 (13–26) 0.02
Stages 1–3 460 (92%) 12 (10–14)
Age (years)
o35 156 (31%) 15 (12–18) 0.09
X35 345 (69%) 12 (9–14)
CI, confidence interval; CLcr, creatinine clearance; HAART, highly active antiretroviral therapy; IQR, interquartile range; WHO, World Health Organization.
aWe used a linear regression model and initially included all covariates that in univariate analyses had Po0.20. We then sequentially dropped each variable that in multivariate
analysis had P40.10. An F-test with 7 degrees of freedom using the Type III sum of squares of the five dropped variables from our saturated model was non-significant
(P=0.84). The six dropped variables from the multivariable analysis were viral load suppression at one year, baseline viral load, weight, BMI, LFT results, and diarrheal disease.
bSeven participants were excluded for incomplete data.
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were identified by the MDRD, which has also been
demonstrated among HIV-infected patients in Western
Kenya.7 Data, however, indicate that the Cockcroft–Gault
equation is more likely to overestimate renal function in
adults with advanced HIV disease,24,25 which suggests that we
may have underestimated the improvements in renal
function. Fourth, our data are subject to survivor bias, as
we excluded participants who died within the first 12 months
of starting HAART and changes in renal function prior to
death in these participants were unknown. Finally, partici-
pants with severe renal dysfunction (CLcr o25 ml/min) at
baseline were also excluded from this study. Although less
than 1% of participants (n¼ 7) were excluded from HBAC
for this indication, we cannot generalize our observations to
HIV-infected persons with more severe renal dysfunction.
Although renal dysfunction may be an important
complication of advanced HIV infection in Africa, among
adults with advanced HIV disease in rural Uganda renal
function improved over 2 years on HAART. Our results
suggest that monitoring renal function with first-line HAART
may not be mandatory. Identifying people infected with HIV
at earlier stages of disease and initiating HAART before severe
complications of renal disease develop may reduce the impact
of HIV-associated renal disease in Africa.
MATERIALS AND METHODS
HBAC is a randomized clinical trial (registered at http://www.cli-
nicaltrials.gov; identifier: NCT00119093) of three different mon-
itoring strategies for HIV-infected individuals receiving HAART in
Tororo and Busia districts of rural Eastern Uganda as previously
described.26 HBAC is a collaboration of the Ugandan Ministry of
Health, The AIDS Support Organization (TASO), the Tororo and
Busia District Health Departments, and the US Centers for Disease
Control and Prevention (CDC). Inclusion criteria required partici-
pants be 18 years or older and have either a CD4-cell count ofp250
cells per mm3 or symptomatic HIV disease (WHO stage 3 or 4
disease or recurrent herpes zoster; isolated pulmonary tuberculosis
was not an inclusion criterion). Participants with baseline CLcr
o25 ml/min (severe renal dysfunction) were excluded from the
study. Of 1171 HIV-infected adults eligible for HAART by clinical
and CD4 cell count criteria, seven (0.6%) were excluded from the
randomized trial because of a CLcr of o25 ml/min. All HBAC
participants received standard weight-based dosages of HAART, but
medications were not adjusted for renal function. Overall adherence
to antiretrovirals was high and 96% of participants had a viral load
of o1000 copies per ml after 1 year on HAART.26 No participants
received tenofovir or indinavir as part of their initial HAART
regimens. In addition to HAART, all participants received
cotrimoxazole prophylaxis and opportunistic infection treatment if
indicated.
The present analysis includes HBAC participants who were
antiretroviral-naive (n¼ 987) and initiated HAART between 1 July
2003 and 31 May 2004.26 A subset of these participants (n¼ 602)
were tested for lipids, liver function tests (LFTs), and creatinine
during treatment.27 The subset was constructed to evaluate changes
in LFTs, and the sample size was determined prospectively based on
calculations made to achieve adequate power to detect differences in
LFT and lipid levels.27 These 602 participants included: (1) a
random subset of 200 women who had survived 24 months on
HAART; (2) all 209 men who had survived 24 months on HAART;
and (3) 193 additional participants who either had a LFT elevation
at baseline (n¼ 129), had died during the first 12 months after
starting HAART (n¼ 72), or had a baseline CD4 cell count of 4250
cells per mm3 (n¼ 19). As we wanted to evaluate changes in renal
function on HAART, we limited our primary analysis to the 508
participants who had been followed for at least 24 months after
HAART initiation and had creatinine results at baseline and at their
12- and 24-month follow-up visits. The 96 participants excluded
from the renal analysis had either died during the first 12 months
after starting HAART (n¼ 72) or were lost to follow-up (n¼ 24).
Overall, the 508 renal study participants were significantly more
likely to be male, older, have a higher BMI, and have a baseline LFT
elevation compared with the entire HBAC cohort. There was no
difference, however, in baseline CD4 cell count or viral load. All
analyses in this manuscript were repeated after excluding the
additional participants (LFT elevation at baseline or a baseline CD4
cell count of 4250 cells per mm3) and we obtained similar results
(data not shown). We elected, therefore, to include these additional
participants in the primary renal analysis, as they had a similar
proportion of participants with renal dysfunction (defined as a CLcr
of 25–50 ml/min) at baseline as the entire HBAC cohort. As this
selection process excludes any participant who has died in follow-
up, in a separate analysis we also compared the baseline renal
function of the 72 HBAC participants who died within the first 12
months of starting HAART with the 508 renal analysis participants
who survived 24 months on HAART.
CLcr, an estimate of the glomerular filtration rate, was calculated
using the Cockcroft–Gault equation28 at each time point. Glomer-
ular filtration rate was also estimated using the simplified MDRD
equation.29 CLcr could not be calculated for three participants who
lacked baseline weight measurements. Renal dysfunction was
defined as a CLcr of 25–50 ml/min. We dichotomized renal function
at 50 ml/min because HIV treatment guidelines recommend dosage
modifications for several antiretrovirals with CLcr of p50 ml/
min.1,30 We repeated the analysis with renal function dichotomized
at 60 ml/min and obtained similar results (data not shown). Serum
specimens were drawn at participants’ homes by field phlebotomists
and transported to the CDC laboratory at the Uganda Virus
Research Institute in Entebbe for processing, testing, and storage.
Serum concentrations of creatinine were assessed using the Jaffe
reaction (Randox CREA CR510, Randox Laboratories Ltd, Crumlin,
UK). The National Institutes of Health Division of AIDS (DAIDS)
table for grading the severity of adult and pediatric adverse events
classifies a creatinine greater than or equal to 1.4 times the upper
limit of normal (ULN; in our lab ULN¼ 97 mmol/l) as moderately
abnormal,31 which corresponded to a serum creatinine of
X133mmol/l (1.5 mg per 100 ml). Baseline diarrheal disease was
used as a surrogate for baseline dehydration in this cohort.
Differences in serum creatinine, CLcr, and change in CLcr over
24 months on HAART between comparison groups were tested by
the Wilcoxon rank sum test (continuous variables), the Wilcoxon
signed-rank test (continuous, matched variables), the w2 test
(dichotomous variables), and McNemar’s test (matched, nominal
variables). P-values o0.05 were considered statistically significant.
We used a multivariable linear regression model to identify variables
independently associated with changes in CLcr from baseline to 24
months. The model was created using general linear modeling (SAS
Proc GLM) with calculation of the least-squares means (LSMEANS).
LSMEANS were also weighted with the observed marginals option
so that changes in coefficients were proportional to the input
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dataset. Dichotomous variables in univariate analysis that were
associated (Po0.20) with a change in CLcr from baseline to 24
months were included in the GLM models. We then sequentially
dropped each variable with P40.10 to create a parsimonious model
and manually reviewed the results after each step to ensure that our
parsimonious model did not significantly differ from our original
saturated model. We also performed an F-test using the Type III sum
of squares of the dropped variables from our saturated model to
verify that the dropped variables were not important to the model.
We also used logistic regression to identify variables independently
associated with baseline renal dysfunction. All variables in univariate
analysis that were associated (Po0.20) with renal dysfunction at
baseline were included in that model. Analyses were performed
using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA).
Written informed consent to participate in HBAC was obtained
from each participant in English or one of the six local languages. The
Uganda National Council of Science and Technology (FWA no.
00001293) and the Institutional Review Boards of the Uganda Virus
Research Institute (IRB no. 00001693) and CDC (IRB no. 00000183–
185) approved the main study (HBAC) and this renal analysis.
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